This Article Full Text Full Text (PDF) All Versions of this Article: 36/7/1619    most recent 01.STR.0000170714.43167.34v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Broderick, J. P. Search for Related Content PubMed PubMed Citation Articles by Broderick, J. P.

(Stroke. 2005;36:1619.)
© 2005 American Heart Association, Inc.

Emerging Therapies

The STICH Trial

What Does It Tell Us and Where Do We Go From Here?

From the Department of Neurology, University of Cincinnati College of Medicine, Ohio.

Correspondence to Joseph Broderick, Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, OH 45267. E-mail Joseph.Broderick@uc.edu.

Section Editors: Marc Fisher MD Antoni Dávalos MD

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Until the present, intracerebral hemorrhage (ICH) has been the stroke subtype that has defied attempts to find a scientifically proven effective therapy. Possible treatments of acute ICH include: (1) slowing or stopping of the bleeding during the first several hours after onset or (2) removal of the accumulated hematoma to prevent the mechanical complications of mass effect as well as the toxic effects of blood on the surrounding brain parenchyma. Critical care management of the complications of ICH is clearly important. The evolution of lesions and the pathophysiology of intracerebral hemorrhage, like that of ischemic stroke, are time-dependent,^1,2 but only the recently published trials of Novo VII have tried to intervene during the first hours after onset of ICH.^3,4 The recent publication of the Novo VII phase II trial also provides hope that an effective treatment for acute ICH is within reach.

The STICH Trial represents an important milestone in the role of surgical treatment for ICH.⁵ The relative paucity of data from randomized trials has severely limited progress in the surgical treatment of ICH and has led to substantial variability in the management of ICH throughout the world. Dr Mendelow, collaborators, and the Medical Research Council (MRC) are to be congratulated for completing the largest ever randomized treatment trial of ICH. This trial adds substantially to what we know about surgical management of ICH and will have an impact on current treatment as well as design of future trials.

The goal of the STICH Trial was to investigate the . . . [Full Text of this Article]